NCT02464605View on ClinicalTrials.gov

Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

July 31, 2016

Conditions
Gout
Interventions
BIOLOGICAL

SEL-037 (pegsiticase)

Intravenous infusion of SEL-037

Trial Locations (2)

16635

Altoona Center for Clincal Research, Duncansville

75231

Metroplex Clinical Research Center, Dallas

All Listed Sponsors
lead

Selecta Biosciences, Inc.

INDUSTRY

NCT02464605 - Safety and Pharmacodynamics of SEL-037 (Pegsiticase) in Subjects With Elevated Blood Uric Acid Levels | Biotech Hunter | Biotech Hunter